phrykt

Actinium Pharmaceuticals, Inc. (ATNM): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of ATNM were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No ATNM insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ATNM short interest

Low short interest. 1.9% of ATNM shares are sold short: about 1 share in 53. Over the last 12 reports the number of shares short went down 43%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 593,218 ATNM shares were sold short, 1.9% of the shares outstanding, down 6.0% from the report before. At the average daily volume of 351,970 shares, buying them all back would take about 1.7 trading days (days to cover).

Shares short, % of all shares

1.89%May 15Oct 303.68%

Days to cover

1.7May 15Oct 3012.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026593,2181.89%-6%351,9701.7
Oct 15, 2026631,2342.01%-11%132,1404.8
Sep 30, 2026705,8562.24%-0%81,2898.7
Sep 15, 2026707,6722.25%+6%204,8473.5
Aug 31, 2026670,6442.13%-13%146,6664.6
Aug 14, 2026768,5042.44%-2%223,6003.4
Jul 31, 2026786,9812.51%-4%76,00110.3
Jul 15, 2026820,0772.61%-12%95,0728.6
Jun 30, 2026936,7082.99%+1%139,4946.7
Jun 15, 2026927,4612.96%-14%161,7045.7
May 29, 20261.08M3.45%+3%96,95911.2
May 15, 20261.05M3.34%-1%122,1378.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Actinium Pharmaceuticals company events

Actinium Pharmaceuticals filed 7 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership, listing). The latest was on Oct 15, 2026.

  1. Oct 15, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. Filing
  2. Aug 14, 2026ListingAs previously disclosed, on May 27, 2026, Actinium Pharmaceuticals, Inc. received notice from NYSE American LLC that the Company was not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide. Filing
  3. Jun 18, 2026AnnouncementIn accordance with the NYSE American LLC requirements, on June 18, 2026, Actinium Pharmaceuticals, Inc. submitted its compliance plan to NYSE American, outlining certain actions management intends to take in effort to restore compliance with applicable listing standards. Filing
  4. May 29, 2026ListingActinium Pharmaceuticals, Inc. received a notice from NYSE American LLC indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide, which requires a listed company to maintain stockholders’ equity of $4.0… Filing
  5. Mar 26, 2026VoteAmended an earlier report. Reported shareholder vote results. Filing
  6. Feb 13, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
  7. Nov 26, 2025LeadershipActinium Pharmaceuticals, Inc. held its 2025 annual meeting of stockholders. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Actinium Pharmaceuticals financials

Famous investors that hold ATNM

3 of the 50 well-known investors we track reported holding ATNM in their latest 13F filing. The largest position is Israel Englander's, worth $542K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026483,666$542K0.0%-6%
Jim Simons · Renaissance TechnologiesQ3 2026342,589$384K0.0%-10%
Ken Griffin · Citadel AdvisorsQ3 202613,921$15.6K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Actinium Pharmaceuticals, Inc. (ATNM) stock

Are ATNM insiders buying or selling?

No ATNM insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in ATNM?

As of Oct 30, 2026, 593,218 ATNM shares were sold short, 1.9% of the shares outstanding, down 6.0% from the report before. At the average daily volume of 351,970 shares, buying them all back would take about 1.7 trading days (days to cover). See the history.

Which famous investors hold ATNM?

3 of the 50 well-known investors we track reported ATNM in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $542K. See all holders.

Executive pay

Actinium Pharmaceuticals's chief executive was paid a total of $1.2M for the year ended Dec 31, 2024, down 75% from $4.7M the year before. In the last 12 months, Actinium Pharmaceuticals's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$1.2MYear ended Dec 31, 2024. Salary, bonus and the value of stock and option awards when granted.
Other top executives, average$582KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.